Cigna Investments Inc. New Buys 850 Shares of Zoetis Inc (NYSE:ZTS)

Cigna Investments Inc. New grew its stake in shares of Zoetis Inc (NYSE:ZTS) by 3.3% in the first quarter, according to the company in its most recent filing with the SEC. The firm owned 26,738 shares of the company’s stock after acquiring an additional 850 shares during the quarter. Cigna Investments Inc. New’s holdings in Zoetis were worth $3,146,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Institute for Wealth Management LLC. bought a new stake in shares of Zoetis during the 4th quarter valued at $25,000. TI Trust Inc. bought a new stake in shares of Zoetis during the 4th quarter valued at $26,000. ICW Investment Advisors LLC acquired a new position in shares of Zoetis during the 4th quarter worth $27,000. Savior LLC acquired a new position in shares of Zoetis during the 4th quarter worth $30,000. Finally, Lion Street Advisors LLC acquired a new position in shares of Zoetis during the 1st quarter worth $30,000. Hedge funds and other institutional investors own 91.35% of the company’s stock.

A number of equities analysts have recently commented on the company. Bank of America reissued a “hold” rating and set a $145.00 price target on shares of Zoetis in a report on Wednesday, February 12th. Citigroup lowered their price target on Zoetis from $139.00 to $131.00 and set a “neutral” rating for the company in a report on Friday, May 8th. SunTrust Banks reissued a “hold” rating and set a $145.00 price target on shares of Zoetis in a report on Friday, February 14th. Morgan Stanley lowered their target price on Zoetis from $148.00 to $125.00 and set an “equal weight” rating for the company in a report on Thursday, April 2nd. Finally, Goldman Sachs Group reaffirmed a “buy” rating and issued a $162.00 target price on shares of Zoetis in a report on Friday, February 28th. Seven research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of “Buy” and an average price target of $139.00.

In other Zoetis news, CFO Glenn David sold 43,778 shares of the stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $140.89, for a total value of $6,167,882.42. Following the transaction, the chief financial officer now owns 36,885 shares in the company, valued at $5,196,727.65. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Kristin C. Peck sold 11,925 shares of the stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $138.10, for a total value of $1,646,842.50. Following the completion of the sale, the chief executive officer now directly owns 51,799 shares of the company’s stock, valued at $7,153,441.90. The disclosure for this sale can be found here. In the last quarter, insiders sold 66,844 shares of company stock worth $9,264,589. Corporate insiders own 0.17% of the company’s stock.

Shares of Zoetis stock traded down $0.22 on Friday, hitting $130.11. 1,594,563 shares of the company’s stock traded hands, compared to its average volume of 2,399,752. Zoetis Inc has a one year low of $90.14 and a one year high of $146.26. The company has a debt-to-equity ratio of 2.22, a current ratio of 2.77 and a quick ratio of 1.91. The company has a fifty day moving average of $125.87 and a two-hundred day moving average of $128.04. The company has a market capitalization of $61.90 billion, a price-to-earnings ratio of 35.13, a price-to-earnings-growth ratio of 4.65 and a beta of 0.78.

Zoetis (NYSE:ZTS) last announced its earnings results on Wednesday, May 6th. The company reported $0.95 EPS for the quarter, beating the consensus estimate of $0.86 by $0.09. Zoetis had a return on equity of 67.72% and a net margin of 25.41%. The company had revenue of $1.53 billion for the quarter, compared to analyst estimates of $1.50 billion. During the same quarter in the prior year, the company earned $0.88 EPS. The firm’s revenue for the quarter was up 5.4% compared to the same quarter last year. Equities research analysts anticipate that Zoetis Inc will post 3.32 earnings per share for the current year.

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 17th will be issued a $0.20 dividend. The ex-dividend date is Thursday, July 16th. This represents a $0.80 annualized dividend and a yield of 0.61%. Zoetis’s payout ratio is currently 21.98%.

Zoetis Profile

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Featured Article: What is cost of equity?

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.